Michele E. Murdoch

Dr. Michele E. Murdoch


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
AFArmelle Forrer
Armelle Forrer
SWSamuel Wanji
Samuel Wanji
EOElisabeth Dibando Obie
Elisabeth Dibando Obie
TNTheobald Mue Nji
Theobald Mue Nji
LHLouise Hamill
Louise Hamill
MTMark J Taylor
Mark J Taylor
Introduction Onchocerciasis is targeted for elimination mainly with annual community-directed treatment with ivermectin (CDTI). High infection levels have been reported in South-West Cameroon, despite ≥15 years of CDTI. The aim of this study was to assess factors associated with continued onchocerciasis transmission and skin disease. Methods A large-scale cross-sectional study was conducted in 2017 in 20 communities in a loiasis-risk area in South-West Cameroon. A mixed-methods approach was used. Associations between infection levels, skin disease and adherence to CDTI were assessed using mixed regression modelling. Different community members’ perception and acceptability of the CDTI strategy was explored using semi-structured interviews. Results Onchocerciasis prevalence was 44.4% among 9456 participants. 17.5% of adults were systematic non-adherers and 5.9% participated in ≥75% of CDTI rounds. Skin disease affected 1/10 participants, including children. Increasing self-reported adherence to CDTI was associated with lower infection levels in participants aged ≥15 years but not in children. Adherence to CDTI was positively influenced by perceived health benefits, and negatively influenced by fear of adverse events linked with economic loss. Concern of lethal adverse events was a common reason for systematic non-adherence. Conclusion CDTI alone is unlikely to achieve elimination in those high transmission areas where low participation is commonly associated with the fear of adverse events, despite the current quasi absence of high-risk levels of loiasis. Such persisting historical memories and fear of ivermectin might impact adherence to CDTI also in areas with historical presence but current absence of loiasis. Because such issues are unlikely to be tackled by CDTI adaptive measures, alternative strategies are needed for onchocerciasis elimination where negative perception of ivermectin is an entrenched barrier to community participation in programmes.

10 October 2014 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
JBJean-Claude MAKENGA BOF
Jean-Claude MAKENGA BOF
VMV. Maketa
V. Maketa
DBD. K. Bakajika
D. K. Bakajika
FNF. Ntumba
F. Ntumba
DMD. Mpunga
D. Mpunga
PLP. Lutumba
P. Lutumba

26 July 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
NMNatalie V. S. Vinkeles Melchers
Natalie V. S. Vinkeles Melchers
WSWilma A. Stolk
Wilma A. Stolk
WLWelmoed van Loon
Welmoed van Loon
BPBelén Pedrique
Belén Pedrique
RBRoel Bakker
Roel Bakker
LCLuc E. Coffeng
Luc E. Coffeng
Background: Onchocerciasis (“river blindness”) can cause severe morbidity, including vision loss and various skin manifestations, and is targeted for elimination using ivermectin mass drug administration (MDA). We calculated the number of people with Onchocerca volvulus infection and onchocercal skin and eye disease as well as disability-adjusted life years (DALYs) lost from 1990 through to 2030 in areas formerly covered by the African Programme for Onchocerciasis Control. Methods: Per MDA implementation unit, we collated data on the pre-control distribution of microfilariae (mf) prevalence and the history of control. Next, we predicted trends in infection and morbidity over time using the ONCHOSIM simulation model. DALY estimates were calculated using disability weights from the Global Burden of Disease Study. Results: In 1990, prior to MDA implementation, the total population at risk was 79.8 million with 26.0 million (32.5%) mf-positive individuals, of whom 17.5 million (21.9%) had some form of onchocercal skin or eye disease (2.5 million DALYs lost). By 2030, the total population was predicted to increase to 236.1 million, while the number of mf-positive cases (about 6.8 million, 2.9%), people with skin or eye morbidity (4.2 million, 1.8%), and DALYs lost (0.7 million) were predicted to decline. Conclusions: MDA has had a remarkable impact on the onchocerciasis burden in countries previously under the APOC mandate. In the few countries where we predict continued transmission between now and 2030, intensified MDA could be combined with local vector control efforts, or the introduction of new drugs for mopping up residual cases of infection and morbidity.

4 December 2019 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
SWSamuel Wanji
Samuel Wanji
TNTheobald Mue Nji
Theobald Mue Nji
LHLouise Hamill
Louise Hamill
LDLaura Dean
Laura Dean
KOKim Ozano
Kim Ozano
MTMark J. Taylor
Mark J. Taylor
Background: Onchocerciasis is a priority neglected tropical disease targeted for elimination by 2025. The standard strategy to combat onchocerciasis is annual Community-Directed Treatment with ivermectin (CDTi). Yet, high prevalence rates and transmission persist following > 12 rounds in South-West Cameroon. Challenges include programme coverage, adherence to, and acceptability of ivermectin in an area ofLoa loaco-endemicity. Loiasis patients harbouring heavy infections are at risk of potentially fatal serious adverse events following CDTi. Alternative strategies are therefore needed to achieve onchocerciasis elimination where CDTi effectiveness is suboptimal.Methods/design: We designed an implementation study to evaluate integrating World Health Organisation-endorsed alternative strategies for the elimination of onchocerciasis, namely test-and-treat with the macrofilaricide, doxycycline (TTd), and ground larviciding for suppression of blackfly vectors with the organophosphate temephos. A community-based controlled before-after intervention study will be conducted among > 2000 participants in 20 intervention (Meme River Basin) and 10 control (Indian River Basin) communities. The primary outcome measure isO. volvulusprevalence at follow-up 18-months post-treatment. The study involves four inter-disciplinary components: parasitology, entomology, applied social sciences and health economics. Onchocerciasis skin infection will be diagnosed by skin biopsy andLoa loainfection will be diagnosed by parasitological examination of finger-prick blood samples. A simultaneous clinical skin disease assessment will be made. Eligible skin-snip-positive individuals will be offered directly-observed treatment for 5 weeks with 100 mg/day doxycycline. Transmission assessments of onchocerciasis in the communities will be collected post-human landing catch of the local biting blackfly vector prior to ground larviciding with temephos every week (0.3 l/m3) until biting rate falls below 5/person/day. Qualitative research, including in-depth interviews and focus-group discussions will be used to assess acceptability and feasibility of the implemented alternative strategies among intervention recipients and providers. Health economics will assess the cost-effectiveness of the implemented interventions.Conclusions: Using a multidisciplinary approach, we aim to assess the effectiveness of TTd, alone or in combination with ground larviciding, following a single intervention round and scrutinise the acceptability and feasibility of implementing at scale in similar hotspots of onchocerciasis infection, to accelerate onchocerciasis elimination.

11 June 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
NMNatalie V. S. Vinkeles Melchers
Natalie V. S. Vinkeles Melchers
WSWilma A. Stolk
Wilma A. Stolk
MMMichele E. Murdoch
Michele E. Murdoch
BPBelén Pedrique
Belén Pedrique
MKMarielle Kloek
Marielle Kloek
LCLuc E. Coffeng
Luc E. Coffeng
Background: Onchocerciasis (river-blindness) in Africa is targeted for elimination through mass drug administration (MDA) with ivermectin. Onchocerciasis may cause various types of skin and eye disease. Predicting the impact of MDA on onchocercal morbidity is useful for future policy development. Here, we introduce a new disease module within the established ONCHOSIM model to predict trends over time in prevalence of onchocercal morbidity. Methods: We developed novel generic model concepts for development of symptoms due to cumulative exposure to dead microfilariae, accommodating both reversible (acute) and irreversible (chronic) symptoms. The model was calibrated to reproduce pre-control age patterns and associations between prevalences of infection, eye disease, and various types of skin disease as observed in a large set of population-based studies. We then used the new disease module to predict the impact of MDA on morbidity prevalence over a 30-year time frame for various scenarios. Results: ONCHOSIM reproduced observed age-patterns in disease and community-level associations between infection and disease reasonably well. For highly endemic settings with 30 years of annual MDA at 60% coverage, the model predicted a 70% to 89% reduction in prevalence of chronic morbidity. This relative decline was similar with higher MDA coverage and only somewhat higher for settings with lower pre-control endemicity. The decline in prevalence was lowest for mild depigmentation and visual impairment. The prevalence of acute clinical manifestations (severe itch, reactive skin disease) declined by 95% to 100% after 30 years of annual MDA, regardless of pre-control endemicity. Conclusion: We present generic model concepts for predicting trends in acute and chronic symptoms due to history of exposure to parasitic worm infections, and apply this to onchocerciasis. Our predictions suggest that onchocercal morbidity, in particular chronic manifestations, will remain a public health concern in many epidemiological settings in Africa, even after 30 years of MDA.

20 October 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
RYRie Yotsu
Rie Yotsu
Claire FullerClaire Fuller
Claire Fuller
MMMichele E. Murdoch
Michele E. Murdoch
CRChandrakant Revankar
Chandrakant Revankar
YBYves Thierry Barogui
Yves Thierry Barogui
Roderick J.  HayRoderick J. Hay
Roderick J. Hay
On 8 June 2022, the World Health Organization (WHO) published ‘Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases’.1 It builds on earlier work ‘A road map for neglected tropical diseases 2021–2023’ and earlier WHO initiatives with a skin focus, including a training manual and a Skin NTD app.2,3 Neglected tropical diseases (NTDs) are diseases usually endemic in poor and relatively isolated regions that have been ‘neglected’ by public health initiatives, research and drug development. Skin-related neglected tropical diseases, or the skin NTDs, are those that produce signs and symptoms on the skin, many of which are diagnosed and managed by dermatologists. It is estimated that more than 1 billion people are either at risk of, or affected by, one or more of the skin NTDs (Table 1 and Figure 1). The framework was developed to enable endemic countries to tailor and incorporate recommendations into their existing national health plans and programmes. The approach specifically recognizes that skin diseases in general are common in these same areas and that these should also be addressed.